The differences in drug disposition gene induction by rifampicin and rifabutin are unlikely due to different effects on important pregnane X receptor (NR1I2) splice variants.
Expression
Pregnane X receptor
Primary human hepatocytes
Rifabutin
Rifampicin
Splice variant
Journal
Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264
Informations de publication
Date de publication:
04 2024
04 2024
Historique:
received:
14
08
2023
accepted:
02
10
2023
medline:
14
3
2024
pubmed:
18
10
2023
entrez:
18
10
2023
Statut:
ppublish
Résumé
Rifampicin and rifabutin can activate the pregnane X receptor (PXR, NR1I2), thereby inducing pharmacokinetically important genes/proteins and reducing exposure to co-administered drugs. Because induction effects vary considerably between these antibiotics, differences could be due to unequal rifamycin-induced activation or tissue expression of the three major NR1I2 splice variants, PXR.1 (NM_003889), PXR.2 (NM_022002), and PXR.3 (NM_033013). Consequently, PXR activation (PXR reporter gene assays) and mRNA expression levels of total NR1I2, PXR.1, PXR.2, and PXR.3 were investigated by polymerase chain reaction in colon and liver samples from eleven surgical patients, in LS180 cells, and primary human hepatocytes. Compared to the colon, total NR1I2 mRNA expression was higher in the liver. Both tissues showed similar expression levels of PXR.1 and PXR.3, respectively. PXR.2 was not quantifiable in the colon samples. Rifampicin and rifabutin similarly enhanced PXR.1 and PXR.2 activity when transfected into LS180 cells, while PXR.3 could not be activated. In LS180 cells, rifampicin (10 μM) reduced total NR1I2 and PXR.3 expression 2-fold after 24 h, while rifabutin (10 μM) increased total NR1I2, PXR.1, PXR.2, and PXR.3 mRNA by approx. 50% after 96-h exposure. In primary human hepatocytes, rifampicin (10 μM) suppressed total NR1I2, PXR.1, and PXR.3 after 48-h exposure, and rifabutin (10 μM) had no significant impact on total NR1I2 or any of the splice variants studied. In conclusion, both antibiotics activated the studied PXR splice variants similarly but modified their expression differently. While rifampicin can suppress mRNA of PXR forms, rifabutin rather increases their expression levels.
Identifiants
pubmed: 37851058
doi: 10.1007/s00210-023-02768-z
pii: 10.1007/s00210-023-02768-z
pmc: PMC10933196
doi:
Substances chimiques
Pregnane X Receptor
0
Rifampin
VJT6J7R4TR
Receptors, Steroid
0
Rifabutin
1W306TDA6S
Anti-Bacterial Agents
0
RNA, Messenger
0
Cytochrome P-450 CYP3A
EC 1.14.14.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2485-2496Informations de copyright
© 2023. The Author(s).
Références
Arch Biochem Biophys. 1991 Oct;290(1):27-36
pubmed: 1654865
Drug Metab Dispos. 2008 Jun;36(6):1172-80
pubmed: 18332086
Clin Chim Acta. 2009 May;403(1-2):142-4
pubmed: 19232333
J Clin Pharmacol. 2006 Nov;46(11):1356-69
pubmed: 17050801
Drug Metab Dispos. 2004 Mar;32(3):340-7
pubmed: 14977869
PLoS One. 2011 Feb 02;6(2):e16703
pubmed: 21311750
Biochem Biophys Res Commun. 2002 Nov 1;298(3):433-8
pubmed: 12413960
J Hepatol. 2014 Sep;61(3):609-16
pubmed: 24798619
Drug Metab Dispos. 2009 Jun;37(6):1295-304
pubmed: 19251824
Arch Intern Med. 2002 May 13;162(9):985-92
pubmed: 11996607
Basic Clin Pharmacol Toxicol. 2007 Apr;100(4):240-8
pubmed: 17371528
Drug Metab Dispos. 2008 Jan;36(1):169-81
pubmed: 17925385
J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):536-49
pubmed: 20861742
Acta Pharm Sin B. 2020 Jan;10(1):136-152
pubmed: 31998607
Clin Pharmacol Ther. 2003 Sep;74(3):275-87
pubmed: 12966371
Ann Clin Microbiol Antimicrob. 2006 Feb 15;5:3
pubmed: 16480505
Drug Metab Dispos. 2008 Feb;36(2):339-48
pubmed: 17998298
Acta Pharm Sin B. 2016 Sep;6(5):441-449
pubmed: 27709012
Cancer Cell. 2020 Jun 8;37(6):800-817.e7
pubmed: 32516590
Toxicol Appl Pharmacol. 2004 Sep 15;199(3):251-65
pubmed: 15364541
Drug Metab Dispos. 2008 Jun;36(6):1166-71
pubmed: 18347084
J Pharm Pharmacol. 2009 May;61(5):541-58
pubmed: 19405992
Drug Metab Dispos. 2008 Mar;36(3):604-13
pubmed: 18094037
Biochem Pharmacol. 2013 Jan 15;85(2):265-73
pubmed: 23219525
Biochem Pharmacol. 2005 Sep 15;70(6):949-58
pubmed: 16054595
Am J Med Sci. 2008 Feb;335(2):126-36
pubmed: 18277121
Drug Metab Dispos. 2001 Nov;29(11):1454-9
pubmed: 11602521
Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):909-22
pubmed: 18624679
Arch Toxicol. 2023 Aug;97(8):2219-2230
pubmed: 37285043
Mol Pharm. 2007 Mar-Apr;4(2):252-7
pubmed: 17263554
Clin Pharmacol Ther. 2019 Dec;106(6):1290-1298
pubmed: 31152598
Gut. 1995 Feb;36(2):259-67
pubmed: 7883227
Arch Toxicol. 2022 Sep;96(9):2501-2510
pubmed: 35678845
Naunyn Schmiedebergs Arch Pharmacol. 2006 Jan;372(4):291-9
pubmed: 16365780